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Summary lododoxorubicin 80 mg m2 i.v. was given 3 weekly for a maximum of six cycles as first-line
chemotherapy to 14 evaluable women with metastatic breast cancer. The response rate was 14% (95%
confidence intervals 4-40%); median time to progression was 3.5 months (range 0.7 to >9.3) and median
survival was 10.2 months (range 2.3 to >20.4). Neutropenia was the main toxicity but was not associated with
severe sepsis. Two patients had a significant (> 10%) but asymptomatic fall in cardiac ejection fraction; other
toxicities were mild. Plasma pharmacokinetics was studied during the first cycle of treatment. Iododoxorubicin
was extensively metabolised to iododoxorubicinol. Neutropenia and thrombocytopenia were both significantly
correlated with the area under the concentration-time curve (AUC) for iododoxorubicin and the total AUC
for iododoxorubicin and iododoxorubicinol. Quality of life (QOL), evaluated by self-report questionnaire and
interview, showed little evidence of benefit in terms of physical symptom relief, level of activity, psychological
symptoms or global evaluation of QOL during treatment. lododoxorubicin is subjectively less toxic than
standard anthracyclines, but at the dose and schedule used has limited activity in metastatic breast cancer,
possibly because iododoxorubicinol is not clinically active.
Doxorubicin is one of the most important agents in the
treatment of solid tumours. There has been considerable
interest in the development of new anthracyclines, of which
epirubicin and idarubicin have entered clinical use. There
remains, however, a need for anthracyclines with either
greater activity or reduced toxicity compared with those cur-
rently in use (Mross, 1991).
lododoxorubicin (4'-iodo-4'-deoxydoxorubicin) differs
from doxorubicin by the substitution of an iodine atom for
the 4'-hydroxyl group on the daunosamine sugar. This results
in iododoxorubicin having a lower pKa and increased
lipophilicity under physiological conditions compared with
doxorubicin (Barbieri et al., 1987). lododoxorubicin had
greater activity than doxorubicin in vitro (Schwartz &
Salmon, 1987) and was cytotoxic against cell lines resistant to
doxorubicin (Barbieri et al., 1987; Supino et al., 1988; Schott
et al., 1990). In vivo, iododoxorubicin was more active than
doxorubicin against the Lewis lung carcinoma (Barbieri et
al., 1987) and less cardiotoxic (Barbieri et al., 1987; Danesi et
al., 1990). In phase I clinical trials (Gianni et al., 1990; Mross
et al., 1990) severe neutropenia was the dose-limiting toxicity.
The phase II evaluation of a new cytotoxic drug typically
concentrates on its clinical activity and toxicity. Recently, the
importance of pharmacological studies in phase II clinical
trials has been emphasised by Judson (1990). This may be the
only opportunity to study the pharmacology of new drugs
given as single agents. Those without activity will not be
developed further and potentially useful cytotoxics may be
discarded. Another important factor, especially in evaluating
drugs to be used with palliative intent, is that conventional
toxicity measures give an incomplete picture of the
tolerability and acceptability of treatment to patients. This is
best achieved by formal assessments ofquality of life (Osoba,
1991).
This phase II study aimed to appraise fully the clinical
activity, toxicity, pharmacology, and effect on quality of life
of iododoxorubicin in patients with advanced breast cancer.
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Patients and methods
Patients
Eligible women had histologically confirmed breast cancer
with measurable metastatic or locally recurrent disease. They
had not received prior chemotherapy for advanced disease
but previous adjuvant chemotherapy excluding anthracyclines
was permitted. Prior endocrine treatment and radiotherapy
were allowed, provided no more than 30% of haemo-
poietically active marrow had been irradiated (Ellis, 1961).
Other eligibility criteria included: WHO performance status
0-2, age 18-75 years, neutrophils >2.0 x 1091- and
platelets > 150 x I0 1-', and bilirubin <35 5.tmol I' with
serum transaminases no more than twice the upper limit of
the reference range. Patients with a history of significant
cardiac disease or a left ventricular ejection fraction (LVEF)
below the normal range, brain metastases or a previous
history of other malignancy were excluded.
Treatment toxicity was assessed according to WHO criteria
(WHO, 1979) and response by UICC criteria (Hayward et
al., 1981). Response duration, progression-free interval and
survival were measured from the date of the first cycle of
iododoxorubicin.
All patients gave informed, written consent separately for
the clinical study and pharmacokinetics. Both studies were
approved by the Guy's Hospital ethics committee.
Treatment plan
Patients received iododoxorubicin as an intravenous (i.v.)
injection every 3 weeks, initially at a dose of 80 mg m 2 over
2-5 min. Three patients, all of whom were more than 150%
of their ideal body weight, received the first cycle of treat-
ment at a dose based on their ideal surface area. Treatment
was delayed if the blood count had not recovered. The dose
was reduced by 10% in the event of clinically significant
infection, WHO grade 3 or 4 mucositis or febrile neutro-
penia. Nadir blood counts were taken but dose adjustments
were not made according to these counts alone. Patients
routinely received metoclopramide 10 mg i.v. alone as
antiemetic cover with other antiemetics given as necessary.
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Prophylactic oral antibiotics were given at the discretion of
the clinician during periods of neutropenia.
A maximum of six cycles of iododoxorubicin were given.
Cardiac function was assessed clinically every 3 weeks. Gated
cardiac (MUGA) scans were performed before treatment,
after three cycles of chemotherapy and before each subse-
quent cycle. In patients developing congestive cardiac failure
or a fall of more than 10% in LVEF iododoxorubicin was
stopped.
Clinicalpharmacology
Thirteen blood samples were taken from each patient
through an indwelling venous cannula over the 48 h follow-
ing the first injection of iododoxorubicin, centrifuged and the
plasma stored at - 20C.
Plasma levels of iododoxorubicin and its metabolites
(iododoxorubicinol, 13-dihydroadriamycinone, 7-deoxyadria-
mycinone and 7-deoxy, 13-hydroadriamycinone) were
measured by high-performance liquid chromatography
(HPLC) and an advanced automated sample processor
(AASP) using a method adapted from one used for
epirubicin (Dobbs & Twelves, 1991). In brief, iododox-
orubicin and its metabolites were extracted from 1 ml plasma
samples onto prepared AASP C2-cartridges which were intro-
duced via the AASP into the stream ofmobile phase [0.019 M
sodium dihydrogen phosphate, pH 3.0, and acetonitrile at
1.86:1 (v/v), flow rate 0.8 ml min-']. Separation was achieved
with a Lichrosorb RP-18 precolumn (particle size 5 gm, col-
umn dimensions 5 cm x 5 mm) and an Apex II ODS
analytical column (particle size 2 ltm, column dimensions
10 cm x 4.6 mm). Fluorescence detection was used (excitation
and emission wavelengths 480 and 550 nm respectively);
idarubicin was the internal standard.
The mean recovery of iododoxorubicin was 65%, and of
its metabolites 71-94%. The routine detection limit was
5 ngml-' for iododoxorubicin, and for the metabolites
1-5 ngml-'. The within-day and day-to-day precision of the
assay were confirmed by coefficients of variation of less than
8% for iododoxorubicin and metabolites over a wide range
of concentrations.
lododoxorubicin pharmacokinetics was fitted to a three-
compartment or a two-compartment model. The 'Pharmkit'
programme (Johnson & Woollard, 1983) was used to obtain
the early (a), intermediate (1) and terminal (r) half-lives.
Mean retention time (MRT, a measure of the period a
molecule remains in the body) was calculated using 'Pharm-
kit'. The area under the concentration-time curve to 48 h
(AUC,) was calculated using the slopes and intercepts derived
from 'Pharmkit', extrapolated back to the end of the injec-
tion and corrected for the duration of the injection (Freed-
man & Workman, 1988). Elimination of iododoxorubicin
from the plasma was expressed as drug clearance (Cl = dose/
AUCL). The volume of distribution of iododoxorubicin was
calculated as V., = dose x AUMC/AUC2 (Benet & Galeazzi,
1979), where AUMC is the area under the first moment
curve.
The AUC, of the metabolites were measured; the ratio, R,
of the AUC, of the metabolites to the AUC, of iododoxo-
rubicin was calculated.
Quality oflife
Assessment of quality of life involved the patient's report of
physical and psychological symptoms, levels of physical
activity, a global evaluation of quality of life and practical
difficulties associated with treatment. These were assessed
using a self-report questionnaire, the Rotterdam Symptom
Check List (RSCL; de Haes et al., 1990) administered before
treatment and 6 weeks after the first cycle of chemotherapy.
A semistructured interview was also conducted after the com-
pletion of treatment.
The RSCL includes these seven items concerned with
psychological symptoms: feeling worried, irritable, nervous,
depressed, anxious, tense and despondent about the future. It
also incorporates a range of physical symptoms and a global
rating of performance status. Patients were asked to rate
these items according to their experience during the previous
week. The severity of common side-effects of chemotherapy
in the days after treatment was also elicited. Each item is
scored between 0 (not at all) and 3 (very much). An interview
after the treatment course had been completed enquired
about problems arising from practical aspects of treatment.
Patients were also asked how worthwhile they felt their treat-
ment had been and whether overall they felt better, the same
or worse than just before starting chemotherapy.
Statistical methods
The protocol specified a response rate of 60% for demons-
trating significant clinical activity. Time to progession and
survival were calculated from the start of chemotherapy
(Kaplan & Meier, 1958).
Pharmacokinetic parameters were correlated with
haematological parameters measured following the first
course of treatment. Those pharmacokinetic parameters
which were not normally distributed were expressed on a
logl0 scale. The surviving fraction (SF) of blood cells was
expressed on a logl0 scale since this is linearly related to drug
exposure in vitro (Skipper et al., 1970). Pearson's correlation
was used to measure the extent of the pharmacodynamic
relationships. A correlation coefficient (r) >0.5 was con-
sidered to show significant predictive capability since under
those circumstances 25% of the variability in the clinical
value could be accounted for by changes in the phar-
macokinetic parameter.
Changes in quality of life scores between the pretreatment
and 6 week assessment were analysed using the Wilcoxon
signed-rank test. The concordance between the patient's and
clinician's reports of alopecia and nausea and vomiting was
assessed using Fisher's exact test.
Results
Clinical activity and toxicity
Sixteen woman were treated between April and December
1991. Two patients, one who declined to attend for 8 weeks
following her first cycle of iododoxorubicin and one later
found to have a past history of ovarian cancer, were ex-
cluded from the analyses. The pretreatment characteristics of
the remaining 14 evaluable women are shown in Table I.
These 14 patients all received at least two cycles of treat-
ment. Four completed the planned six cycles of
chemotherapy and seven discontinued treatment because of
progressive disease. The three remaining patients, who had
stable disease, stopped iododoxorubicin because of unaccep-
table toxicity (two WHO grade 3 or 4 vomiting, one > 15%
fall in LVEF). A total of 55 cycles of iododoxorubicin were
administered, ofwhich ten cycles were either delayed or given
at a reduced dose. Neutropenia accounted for seven of the
delays or dose reductions, anaemia for two, infection and/or
malaise for two and anticipatory vomiting for one delay.
The median follow-up period was 12.0 months. No patient
had a complete response, but two achieved a partial response
and a further eight had stable disease. The response rate was,
therefore, 2/14 (14%, with 95% confidence intervals 4-40%);
response durations were 4.5 and > 5.6 months. In all, four
responses were seen (three in lymph nodes, one pulmonary
metastasis) from a total of 25 measurable disease sites (16%).
The median time to progression for all 14 evaluable patients
was 3.5 months (range 0.7-11.3 months); median survival
was 10.2 months (range 2.3 to >20.4 months).
The worst toxicity experienced by each patient is shown in
Table II. Neutropenia was the main toxicity and WHO grade
3 or 4 toxicity was associated with 35/55 (64%) treatment
cycles. There were 16 episodes of infection in nine patients,
11 of which were associated with a neutrophil count less than728 C.J. TWELVES et al.
Table I Characteristics of evaluable patients (n = 14)
Median age
ECOG performance status:
0
Histology
Infiltrating ductal
Infiltrating lobular
Other/unknown
Receptor status:
ER positive
negative
unknown
PR positive
negative
unknown
Prior systemic treatment
Adjuvant endocrine
Adjuvant chemotherapy
Advanced endocrine
Percentage active marrow
previously irradiated
None
1-10
>10
Measurable disease sitesa
Cutaneous
Lympathic
Breast
Bone
Visceral
Other
59 (range 39-66)
3
11
9
1
4
5
4
5
2
7
5
6
2
10
3
8
3
4
6
5
6
3 (two lung), one (liver)
1 (pleural)
aNine patients had more than one site of measurable disease. There
were a further six evaluable, but not measurable, sites of disease.
Table II Worst toxicity experienced (out of 14 patients)
WHO grade
Toxicity 0 1 2 3 4
Neutropenia 0 0 1 5 8
Thrombocytopenia 6 2 4 2 0
Anaemia 0 7 5 2 0
Infection 5 8 1 0 0
Stomatitis 7 5 2 0 0
Nausea/vomiting 2 1 7 2 2
Alopecia 4 9 1 0 0
1.0 x 109 1-l, but only one patient was admitted to hospital
whilst neutropenic. Four patients required oral antibiotics for
infections but none received intravenous antibiotics.
Although most patients received metoclopramide as the
only antiemetic, the majority of cycles of chemotherapy were
not associated with clinically significant nausea and vomiting.
Intractable (WHO grade 4) vomiting was, however, recorded
in two patients, one of whom had experienced severe emesis
with adjuvant chemotherapy and later required psychiatric
intervention. The median change in LVEF during treatment
was - 1.5% (range + 18.3% to - 24.1%). Two women, one
of whom had received radiotherapy to the left breast, had
falls in LVEF of 15% and 24.1% after 160 and 320mg m 2
of iododoxorubicin respectively. Neither patient developed
clinical evidence of cardiac failure or ECG abnormalities.
Alopecia, judged by WHO criteria, was mild and stomatitis
was uncommon. One patient experienced an extravasation
causing pain, swelling and erythema which resolved without
ulceration.
Pharmacokinetics andpharmacodynamics
In ten women iododoxorubicin pharmacokinetics fitted a
three-compartment model and the remaining four fitted a
two-compartment model. A typical concentration-time curve
from one patient is shown in Figure 1. The pharmacokinetics
parameters for iododoxorubicin and its metabolites are
shown in Table III. Iododoxorubicin clearance and R for
iododoxorubicinol (Rjd0d,oxKi) were significantly correlated
with body weight (r = 0.52, P = 0.03, and r = 0.65,
P= 0.006, respectively) but not with other morphometric or
biochemical parameters.
Relationships between the AUC, of iododoxorubicin and
iododoxorubicinol and nadir counts after the first cycle of
treatment, represented as absolute values and surviving frac-
tions (SF), are shown in Tables IVa and lVb respectively.
The SF for neutrophils (Figure 2), total WBC and platelets
all correlated with iododoxorubicin AUC,, as did absolute
nadir neutrophil aand platelet counts. In addition, the five
patients with WHO grade 4 neutropenia after their first cycle
ofchemotherapy had a significantly higher median iododoxo-
rubicin AUC, than the eight with lesser degrees of neutro-
penia (532 and 352ngml1'h respectively, P=0.01). In a
multivariate analysis only iododoxorubicin AUC, predicted
for neutropenia (r2=44.6%). Body weight, height, surface
area, pretreatment blood counts, age, and extent of prior
radiotherapy did not predict for neutropenia.
Neither peak iododoxorubicin plasma concentration nor
AUC, correlated with the severity of nausea and vomiting
during the first cycle of treatment or the subsequent fall in
LVEF. Only two patients responded to iododoxorubicin, so
it was not possible to correlate response to treatment with
pharmacokinetics.
Quality oflife
All 14 evaluable patients underwent initial quality of life
assessment; 12 were also evaluable at 6 weeks (two patients
who had discontinued iododoxorubicin did not attend).
Eleven patients later had a post-treatment interview.
The median RSCL psychological score for all 14 patients
prior to treatment was 10 (range 0-17). There was no
significant change in the median RSCL psychological score
for the 12 patients who completed both the pretreatment and
6 week assessments (P = 0.13). Levels of activity prior to
treatment and at 6 weeks appeared to be unchanged (12/14
and 11/12 respectively 'up all day'; 2/14 and 0/12 respectively
'up half the day'; 0/14 and 1/12 respectively 'up only for
short periods' or 'confined to bed').
The most commonly reported physical symptoms and their
prevalence in the week prior to the pretreatment and 6 week
assessments are shown in Table V. Tiredness and lack of
energy were the most prevalent symptoms, with more than
half of patients complaining of the former and about a third
complaining of the latter at both time points. In addition,
5/12 (42%) patients described moderate or severe nausea,
while 1/12 (17%) described similar levels of vomiting in the
days after the second cycle of treatment. There was no
significant difference in the frequency of alopecia or nausea
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Figure 1 Plasma profile of iododoxorubicin and metabolites in a
patient following 80mg m2 iododoxorubicin. (iododoxorubicin,
; iododoxorubicinol, ; 13-
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Table m Pharmacokinetic parameters for iododoxorubicin and its metabolites
Mean value (s.d.)
Parameter I-DOX I-DOXOL 7-Aa 13-A 7, 13-Ab
AUC, 478.3 (315) 4294.0 (1227) 68.0 (69) 363 (439) 135 (89)
(ngml' h)
PPC 481.5 (188) 512.2 (216) 11.6 (9) 22.4 (13) 14 (12)
(ng mlh')
TPPC 7.8 (2.6) 11.6 (7.7) 4.0 (8) 24.4 (60) 120 (150)
(min)
MRT 20.7 (15) - - - -
(h)
Clearance 319.0 (142) - - - -
(Ih-')
Vss 5479.0 (3504) - - - -
(1)
a-tI/2 0.16 (0.17) - - - -
(h)
b-t t2c 0.80 (0.3) - - - -
(h) C-) tl/220.6 (12.0) 11.6 (2.5) 24.2 (18) 20.6 (18) 36 (48)
(h)
R _ 11.8 (3.8) 0.2 (0.3) 0.9 (1.0) 0.4 (0.3)
Abbreviations: I-DOX, iodoxodorubicin; I-DOXOL, iodoxodorubicin; 7-A, 7-deoxyadriamycinone; 13-A,
13-dihydoadriamycinone; 7, 13-A, 7-deoxy, 13-dihydroadriamycinone.
an = 8 patients; 7-A not detected in six women. bn = 13 patients; 7, 13-A not detected in one woman. Cb - tI/2 from
10 patients fitted to a three-compartment model.
Table IVa Relationship between absolute nadir blood counts and AUCs (n = 14)
Correlation coefficients
r (P-value)
AUC Haemoglobin Total WBC Neutrophils Platelets
I-DOX - 0.07 (0.41) - 0.40 (0.07) - 0.54 (0.023) - 0.60 (0.01)
I-DOXOL - 0.16 (0.29) - 0.38 (0.09) -0.58 (0.014) - 0.43 (0.06)
I-DOX + I-DOXOL -0.15 (0.373) -0.41 (0.07) -0.62 (0.01) -0.50 (0.03)
Table IVb Relationship between the surviving fraction (SF) nadir blood counts and AUCs
(n = 14)
Correlation coefficients
r (P-value)
AUC Haemoglobin Total WBC Neutrophils Platelets
I-DOX 0.29 (0.16) - 0.65 (0.001) - 0.67 (0.004) - 0.73 (0.002)
I-DOXOL 0.42 (0.07) - 0.33 (0.13) - 0.45 (0.05) - 0.59 (0.012)
I-DOX + I-DOXOL0.40 (0.08) -0.43 (0.06) -0.53 (0.026) -0.66 (0.005)
Values in bold are significant as defined in the text.
r r=-0.67P=0.004
x x~~~~~~~~~~
x x
x \ x~~~~~~~~~~
x\
x x
Table V Numbers of patients scoring moderately or highly on key
physical items of RSCL
Pretreatment Six weeks
RSCL question n = 14 (%) n = 12 (%)
Been tired? 7 (50) 7 (58)
Been lacking energy? 4 (29) 4 (33)
Been short of breath? 2 (14) 4 (33)
Been in pain? 6 (43) 2 (17)
Been lacking appetite? 3 (21) 0 (0)
Had a dry mouth? 3 (21) 0 (0)
250 400 650 1000 1600
AUCt
Figure 2 Relationship between log10 AUC, for iododoxorubicin
and logl0 SF neutrophils.
and vomiting (both P = 0.2) as reported by the patient and
the clinician. Two of 12 (17%) reported moderate or severe
hair loss at the time. However, one patient described her hair
loss as severe, while the clinician rated it as only WHO grade
1.
The most commonly reported difficulties arising from prac-
tical aspects of treatment were related to the investigations;
half the patients reported moderate or severe problems. The
tests were described as time-consuming and the MUGA scan
as particularly unpleasant. Five of the 11 patients described
significant problems with the chemotherapy injection iself,
including difficulties with venepuncture and an extravasation.
In three women these problems occurred following cannula-
tion by an inexperienced member of the medical staff; subse-
quent cannulations by a nurse specialist were described as
less problematic. Other problems related to frequent hospital
visits (three patients), arranging transport (one), parking
(five) and taking time off work (two).
After completing chemotherapy, four patients felt the
same, seven felt worse and none felt better than they did
before treatment. At this time eight patients felt
chemotherapy had not been at all worthwhile, one a little
0.000*
0.398
n
s Q 0.160 0
4-0
( 0.063
0-
cn 0.025,730 C.J. TWELVES et al.
worthwhile, one moderately worthwhile and only one judged
it as very worthwhile. Neither of the patients who responded
felt treatment had been at all worthwhile.
Discussion
This study, comprising clinical, pharmacokinetic and quality
of life parameters, is a comprehensive evaluation of iododox-
orubicin in patients with advanced breast cancer. The study
closed after 14 evaluable patients had been treated following
a scheduled analysis at which the response rate was 14%
(95% CI 4-40%). Although the confidence intervals are wide,
this response rate is much lower than the 60% response rate
defined in the protocol as representing significant activity for
iododoxorubicin in advanced breast cancer in comparison
with other anthracyclines. Nevertheless, the study provided
useful pharmacological and quality of life data.
The 14% response rate is disappointing given the pre-
clinical activity of iododoxorubicin (Barbieri et al., 1987;
Schwartz & Salmon, 1987; Supino et al., 1988; Schott et al.,
1990). In the earlier phase II studies, Sessa et al. (1991)
reported a response rate of2/20 (10%) in women with metas-
tatic breast cancer. This is lower than that reported by
Gianni et al. (1991); the response rate was 11/31 (35%) in
women with locally advanced disease and 5/15 (33%) in
women with metastatic disease. Despite the higher response
rate, the median response duration was only 53 days in the
latter study (Gianni et al., 1991). Schwartsmann and Pinedo
(1991) suggested that problems of patient selection and dose
intensity in the multicentre study (Sessa et al., 1991) may
explain the lower response rate compared with the single-
centre study from Milan (Gianni et al., 1991).
The current study helps to clarify the activity of iododox-
orubicin in metastatic breast cancer. lododoxorubicin dose
intensity and the frequency of severe neutropenia were very
similar to that seen by the Milan group. The substantially
lower response rate in the current study is, therefore, prob-
ably the result of patient selection. In the 49 women with
metastatic breast cancer reported in the three phase II
studies, a total of nine partial responses have been seen
(18%, CI 10-31%). Together these studies indicate that
iododoxorubicin given 3 weekly at these doses is less active
than either doxorubicin or epirubicin given at standard doses
as first-line chemotherapy for metastatic breast cancer.
The pharmacological data obtained in this phase II study
broadly confirm those of the phase I studies (Gianni et al.,
1990; Mross et al., 1990; Robert et al., 1992). Iododoxo-
rubicin was extensively metabolised to iododoxorubicinol
with the aglycone metabolites being less prominent. The
correlation between RlododoX,oi and weight has not been de-
scribed previously. Metabolic clearance due to conjugation
appears to be enhanced in the obese (Abernathy et al., 1982).
The correlation between both Ri,ododox-ol and clearance of
iododoxorubicin with body weight may be due to increased
activity of the widely distributed aldo-keto reductases, which
metabolise anthracyclines to their alcohols (Loveless et al.,
1978). If iododoxorubicinol is less 'active' than the parent
compound in man, obese patients may be undertreated if
dosage is based on their ideal, or even actual, surface area.
The high value of Riododox-ol emphasises the importance of
iododoxorubicinol in determining the activity in patients
treated with iododocorubicin. Although in vitro the cytotox-
icity of iododoxorubicinol is equal to that of iododox-
orubicin (Schott et al., 1990), Robert et al., (1992) showed
that iododoxorubicinol pentrates human tumours in vivo
much less than iododoxorubicin. The relatively low response
rates to iododoxorubicin in advanced breast cancer suggest that, although the parent compound may be cytotoxic, metabolism to iododoxorubucinol reduces its clinical activity. Interestingly, in mice there is much less metabolism of
iododoxorubicin to iododoxorubicinol (Formelli et al., 1987), and interestingly iododoxorubicin is active against murine
tumours in vivo (Barbieri et al., 1987).
Given the disappointing response rate, it is not surprising
there is little evidence that benefit accrued from treatment in
terms of quality of life. In line with the clinical evaluation,
there was little evidence ofchange in common physical symp-
toms during the first 6 weeks of treatment with the possible
exception of an improvement in pain. Similarly, activity
levels and levels of psychological distress remained largely
unchanged during that time. Three-quarters of the patients
reported that they felt treatment was only 'a little' or 'not at
all' worthwhile. None of the patients felt better than before
starting treatment, and over half felt worse. This study dem-
onstrated how qualify of life data can be collected in a phase
II study, but the value of such data would be better assessed
where the agent under evaluation had activity which had to
be balanced against toxicity. Under those circumstances QOL
data may complement the routinely collected clinical toxicity
data.
Enhanced activity is not the only goal for new anthracyc-
lines, and altered patterns of toxicity may also be important.
With the exception of myelosuppression, WHO treatment-
related toxicities and patients' reported side-effects were
generally mild. Stomatitis, alopecia, nausea and vomiting
were much less severe than with established anthracyclines
given at maximum tolerated doses. The generally good agree-
ment between the patient's and doctor's assessment of
alopecia and nausea and vomiting is encouraging. However,
patients found that practical aspects of the study caused
difficulties. The burden on patients of the additional inves-
tigations, which are a frequent requirement of phase II trials,
should be considered in the design of these studies.
The dose-limiting toxicity of iododoxorubicin, myelosup-
pression, is clearly related to AUC,. By contrast with the
phase I data (Robert et al., 1992), myelosuppression was
more strongly correlated with the AUC of iododoxorubicin
than with that of iododoxorubicinol. Ackland et al. (1989)
reported a correlation between neutropenia and doxorubicin
pharmacokinetics, but such relationships have not been
widely demonstrated. The fall in LVEF seen in two patients
during the current study at relatively low cumulative doses of
iododoxorubicin was unexpected. Only 2 of 96 patients in the
earlier phase II studies had similar changes (Gianni et al.,
1991; Sessa et al., 1991), and in animal models iododoxo-
rubicin is substantially less cardiotoxic than doxorubicin
(Danesi et al., 1990). Although neither patient developed
symptoms of heart failure, cardiac function should be
monitored carefully in future studies.
Taken together, the three published studies suggest modest
activity for iododoxorubicin 80mgml-2 in comparison with
equitoxic doses of doxorubicin or epirubicin. Although
iododoxorubicin has fewer subjective side-effects than other
anthracyclines, at this dose and schedule it appears to be
significantly less active than doxorubicin and epirubicin
against metastatic breast cancer. This was confirmed by the
failure of psychological distress, physical symptoms and
overall quality of life to improve following treatment. This
low response rate may be due to the extensive metabolism of
iododoxorubicin to iododoxorubicinol, which may not be
clinically active. A role for iododoxorubicin in the treatment
of patients with advanced breast cancer remains to be identi-
fied. It may be possible to give iododoxorubicin at higher
doses, especially with the use of colony-stimulating factors,
but such regimens are unlikely to be more cost-effective than
conventional anthracyclines.
The current study shows how a comprehensive assessment
of a new agent can be achieved by combining evaluation of
clinical activity, pharmacokinetics and quality of life in a
single-centre phase II trial. We commend this as a model for
the evaluation of new cytotoxic agents.
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the statistical analyses. lododoxorubicin and pure analytic
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